May 24, 2016.
Eli Lilly today stated it has the potential to launch 20 new products in the 10 years (2014 through 2023).
The company added that it could launch an average of two new indications or line extensions for already-approved products per year during that same time period.
In a presentation to the investment community, Lilly chairman John C. Lechleiter, Ph.D., said: "There are no guarantees given the nature of science and of our business; however, in looking at our recent launches and current pipeline, we believe we are in the midst of the most prolific period of new launches in our company's 140-year history."
Lilly's R&D efforts focus on five therapeutic areas. The four core areas are diabetes, oncology, immunology and neurodegeneration, and one emerging area is pain.
A live audio webcast of Lilly's presentation is available on the "Webcasts & Presentations" section of Lilly's investor website at http://investor.lilly.com/events.cfm
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.